Abstract:Breast cancer is a heterogeneous disease with complex molecular pathogenesis. Overexpression of several tyrosine kinase receptors is associated with poor prognosis, therefore, they can be key targets in breast cancer therapy. Tyrosine kinase inhibitors (TKIs) have emerged as leading agents in targeted cancer therapy due to their effectiveness in disrupting key molecular pathways involved in tumor growth. TKIs target various tyrosine kinases, including the human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), Vascular endothelial growth factor receptor (VEGFR), anaplastic lymphoma kinase (ALK), vascular endothelial growth factor receptor (VEGFR)-associated multi-targets, rearranged during transfection (RET), fibroblast growth factor receptor (FGFR), receptor tyrosine kinase-like orphan signal 1 (ROS1), Mitogen-activated protein kinase (MAPK), and tropomyosin receptor kinase (TRK). These drugs target the tyrosine kinase domain of receptor tyrosine kinases and play a vital role in proliferation and migration of breast cancer cells. Several TKIs, including lapatinib, neratinib, and tucatinib, have been developed and are currently used in clinical settings, often in combination with chemotherapy, endocrine therapy, or other targeted agents. TKIs have demonstrated remarkable benefits in enhancing progression-free and overall survival in patients with breast cancer and have become a standard of care for this population. This review provides an overview of TKIs currently being examined in preclinical studies and clinical trials, especially in combination with drugs approved for breast cancer treatment. TKIs have emerged as a promising therapeutic option for patients with breast cancer and hold potential for treating other breast cancer subtypes. The development of new TKIs and their integration into personalized treatment strategies will continue to shape the future of breast cancer therapy.

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives

Kinase-targeted cancer therapies: progress, challenges and future directions

Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy

Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors

Emerging Roles of Targeted Small Molecule Protein-Tyrosine Kinase Inhibitors in Cancer Therapy

Trends in kinase drug discovery: targets, indications and inhibitor design

A comprehensive review of protein kinase inhibitors for cancer therapy

Tyrosine kinase inhibitors: a clinical perspective

Exploring receptor tyrosine kinases-inhibitors in Cancer treatments

Tyrosine kinase inhibitors in cancers: Treatment optimization - Part I

Kinase Inhibitors FDA-Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities

The Progress of Tyrosine kinase Inhibitors in Cancer Therapy

A review on tyrosine kinase inhibitors for targeted breast cancer therapy

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer: Current Use and Future Prospects

Therapeutic advances of targeting receptor tyrosine kinases in cancer

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Irreversible Kinase Inhibitors Targeting Cysteine Residues and their Applications in Cancer Therapy

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

FDA-approved small molecule kinase inhibitors for cancer treatment (2001-2015): Medical indication, structural optimization, and binding mode Part I